Given that chemotherapy administration is frequently constrained by rapid patient deterioration, including weight loss and impaired glucose metabolism, we aim to investigate the association between these clinical features and the tumor stage/prognosis with the inflammatory interleukin 6 (IL-6)/glycoprotein 130 (GP130)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. This evidence concerns the gene STAT3 and neoplasm.